Biotech | October 15, 2021
Exelixis in-licenses second anti-cancer compound from Aurigene
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
The injection is used to reverse the effects of the muscle relaxants given to patients during surgery
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
RT-PCR test detects and differentiates SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus
This product will be manufactured at Lupin’s Pithampur facility In India
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
The company plans to submit the IND application by the end of 2021
Subscribe To Our Newsletter & Stay Updated
